It has been effective in tumors, including pancreatic cancer, with deficient homologous repair due to BRCA1/2 mutations, where DNA breaks are repaired by more error-prone pathways such as non-homologous end joining, resulting in cell cycle arrest, genetic instability, and cell death [67–69]. Here, BRCA1 is linked to familial pancreatic carcinoma.